GeoVax Stock Rockets Nearly 80% as Tiny Vaccine Developer Grabs Biodefense Spotlight
GeoVax Labs shares closed Monday at $2.21, up 79.7%, after the small vaccine developer announced a $3 million private placement and leaned into investor interest around biodefense preparedness. The stock was indicated lower in early premarket quotations Tuesday, after regular trading had not yet resumed. The timing matters. The World Health Organization declared the Ebola Bundibugyo outbreak in Democratic Republic of Congo and Uganda a Public Health Emergency of International Concern, or PHEIC — its top international alert for an event that needs coordinated action, though not necessarily a pandemic. WHO said the outbreak did not meet pandemic-emergency criteria.
